DTF position on Supporting Clinical Trials During the COVID19 Pandemic
Clinical trials remain critical in the path to bringing innovative drugs, vaccines and therapies to consumers and patients in Australia in a safe and regulated manner. Given the anticipated growing impact of COVID-19 on the health system and a range of services, Clinical Trial Sponsors are working with their doctors and nurses to prepare for disruption to normal research activities due to this pandemic. At all times, the safety and continuity of care of clinical trial participants is the key concern of Clinical Trial Sponsors and clinical trial centre staff.
Clinical Trial Sponsors are committed to the delivery of clinical research and will work to ensure that the clinical trials already underway are managed as well as can be during the pandemic. Clinical Trial Sponsors are working closely with clinical trial centre staff to understand what additional support can be provided to overcome the challenges that are presenting due to COVID-19 disruptions.
Clinical Trial Sponsors acknowledge and will comply with all federal and state health directives and will maintain a watch and act position in relation to these directives
The Research & Development Taskforce has formed a COVID-19 Working Group to support the clinical trials sector as the effects of the COVID -19 pandemic are felt around the nation.
The Working Group will seek to engage with representatives from all sectors including, Pharmaceutical, CRO, Medical Device and Biotechnology companies, Phase I units, Governments and Health Depts, Ethics committees and Governance, and Academic groups.
Click here to view the RTDF position statement on Supporting Clinical Trials During the COVID-19 Pandemic